Damora Therapeutics (DMRA) Long-Term Investments (2021 - 2023)

Damora Therapeutics has reported Long-Term Investments for 3 years, with the latest figure at $4.0 million in Q1 2023.

• For the quarter ending Q1 2023, Long-Term Investments fell 51.42% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2023 stood at $4.0 million (down 51.42% YoY), and the FY2022 full-year result was $5.8 million, down 35.54% from the prior year.
• Long-Term Investments for Q1 2023 stood at $4.0 million, down from $5.8 million in the prior quarter.
• The five-year high for Long-Term Investments was $38.6 million in Q1 2021, with the low at $4.0 million in Q1 2023.
• Historically, Long-Term Investments has averaged $15.6 million across 3 years, with a median of $8.2 million in 2022.
• The largest YoY upside for Long-Term Investments was 35.54% in 2022 against a maximum downside of 80.79% in 2022.
• Damora Therapeutics' Long-Term Investments stood at $9.0 million in 2021, then sank by 35.54% to $5.8 million in 2022, then sank by 32.03% to $4.0 million in 2023.
• The last three Long-Term Investments figures came in at $4.0 million (Q1 2023), $5.8 million (Q4 2022), and $6.8 million (Q3 2022), per Business Quant data.